Recommendations for Use of MenACWY-CRM (Menveo®) In Infants at Increased Risk for Meningococcal Disease - Asplenia - Document - PDFSEARCH.IO

First Page	Meta Content
	Recommendations for Use of MenACWY-CRM (Menveo®) In Infants at Increased Risk for Meningococcal Disease Add to Reading List Document Date: 2013-11-05 13:19:51 Open Document File Size: 218,57 KB Share Result on Facebook City Years / / Company Age Serogroup B Serogroup C Serogroup / Serogroup B Serogroup C Serogroup Y Serogroup / Serogroup C Serogroup Y Serogroup W Serogroup / Vaccine Carrier / Novartis / / Country United States / / MedicalCondition Respiratory Diseases Meningitis / GSK Tetanus / meningococcal disease / sanofi pasteur Diphtheria / Disease / HBV / epidemic / / MedicalTreatment Immunization / vaccination / / Organization MPH Advisory Committee / FDA / / Person Jessica MacNeil / / Technology CRM / / SocialTag Biology Pneumococcal conjugate vaccine Meningococcal vaccine Meningococcal disease DPT vaccine Meningitis Asplenia Haemophilus influenzae NmVac4-A/C/Y/W-135 Vaccines

Recommendations for Use of MenACWY-CRM (Menveo®) In Infants at Increased Risk for Meningococcal DiseaseAdd to Reading List